13 reports

In refractory patients consider adding TZD or SGLT##I: Basal insulin + Mealtime insulin or GLP-## RA TZD SU or or SGLT##I Insulin or or DPP-##I Insulin GLP-## RA + or or TZD Insulin Metformin + Insulin (basal) + or DPP-##I or SGLT##I o

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

A heavy tax on insulin delivery devices such as syringes also hinders effective disease management despite insulin availability.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

Direct Activation of the Angiotensin II Type-## Receptors Enhances Muscle Microvascular Perfusion, Oxygenation and Insulin Delivery in Male Rats".

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Endocrine Disease
  • Type 2 Diabetes
  • World
  • Product Initiative
  • Novartis AG
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Endocrine Disease
  • Pharmaceutical
  • Type 2 Diabetes
  • World
  • Clinical Trial profile. 133 Trial Title
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Diabetic Nephropathy Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Diabetic Nephropathy Global Clinical Trials Review, H2, 2017" provides an overview of Diabetic Nephropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic...

  • Clinical Trial
  • Endocrine Disease
  • Therapy
  • Type 2 Diabetes
  • World

NEVAN ELAM, SAID, " AB ## HAS THE POTENTIAL TO BE A CLEARLY DIFFERENTIATED PRODUCT THAT REPRESENTS A SIGNIFICANT ADVANCE IN BASAL INSULIN DELIVERY.

  • Type 2 Diabetes
  • United States
  • Company
  • Company Financials
  • AntriaBio, Inc.

NEVAN ELAM, SAID, " AB ## HAS THE POTENTIAL TO BE A CLEARLY DIFFERENTIATED PRODUCT THAT REPRESENTS A SIGNIFICANT ADVANCE IN BASAL INSULIN DELIVERY.

  • Type 2 Diabetes
  • United States
  • Company
  • Company Financials
  • AntriaBio, Inc.
  • RECOMBINANT PEPTIDES TO AGONIZE INSULIN RECEPTOR FOR TYPE 1 AND TYPE 2 DIABETES - DRUG PROFILE
  • RECOMBINANT PEPTIDE TO AGONIZE INSULIN RECEPTOR FOR DIABETES - DRUG PROFILE

AEROGEN HAS GRANTED DANCE AN EXCLUSIVE WORLDWIDE LICENSE TO THEIR AEROSOL TECHNOLOGY FOR INSULIN DELIVERY.

  • Biopharmaceutical
  • Pathology
  • Type 2 Diabetes
  • United States
  • Company
  • RECOMBINANT PEPTIDES TO AGONIZE INSULIN RECEPTOR FOR TYPE 1 AND TYPE 2 DIABETES - DRUG PROFILE
  • Type 2 Diabetes - Companies Involved in Therapeutics Development

ORAL GLP-## ANALOGS ARE DEVELOPED BASED ON AXCESS ORAL DELIVERY SYSTEM.

  • Chronic Disease
  • Pathology
  • Pharmaceutical
  • Type 2 Diabetes
  • Company

Direct Activation of the Angiotensin II Type-## Receptors Enhances Muscle Microvascular Perfusion, Oxygenation and Insulin Delivery in Male Rats".

  • Diabetes
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative

Direct Activation of the Angiotensin II Type-## Receptors Enhances Muscle Microvascular Perfusion, Oxygenation and Insulin Delivery in Male Rats".

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative

FDA Phase IIa safety study for ORMD-##, an oral insulin capsule based on the Company' s platform Protein Oral Delivery (POD) technology.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative